Intercell receives "The Vaccine Industry Excellence Award"
Wien (euro adhoc) -
» Intercell's Hepatitis C vaccine candidate was awarded in the category of "Best New Therapeutic Vaccine" at the World Vaccine Congress
» Intercell's therapeutic Hepatitis C vaccine successfully concluded Phase II clinical trials in February 2008
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
Vienna (Austria), April 24, 2008 - In the course of the World Vaccine Congress in Washington D.C., USA, Intercell was awarded "The Vaccine Industry Excellence Award" in the category "Best New Therapeutic Vaccine" for its therapeutic Hepatitis C (HCV) vaccine candidate.
Earlier this year, Intercell's therapeutic vaccine candidate against HCV successfully concluded Phase II clinical trials. The novel vaccine is designed to stimulate T-cell responses against viral protein structures conserved throughout the major HCV genotypes in order to reduce viral load in the blood of chronically infected patients.
"We are pleased to receive this award for our novel therapeutic Hepatitis C vaccine. The latest Phase II data provides a strong base to further strengthen our Hepatitis C franchise and to accelerate our efforts towards a most valuable potential component in a combination treatment for HCV," stated Alexander von Gabain, Chief Scientific Officer of Intercell.
To improve and accelerate the development of a therapeutic Hepatitis C vaccine, Intercell and its partner Novartis will take advantage of an enlarged antigen portfolio and of IC31®, Intercell´s second-generation adjuvant.
With representatives from over 200 individual companies, the "World Vaccine Congress", taking place in Washington D.C. (USA) from April 21-24, 2008, is one of the largest and most important vaccine industry meetings this year.
end of announcement euro adhoc
Further inquiry note:
Head of Communications
Tel. +43 1 20620-303
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market